Evidence map›Paper›PMID 29085180›Full record

ArticleDisease markers2017

Malignant Mesothelioma, BAP1 Immunohistochemistry, and VEGFA: Does BAP1 Have Potential for Early Diagnosis and Assessment of Prognosis?

Emily Pulford, Kalyani Huilgol, David Moffat, Douglas W Henderson, Sonja Klebe

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Disease markers, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it, 54 citations in OpenAlex.

  1. Guideline
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Can BAP1 expression loss in mesothelial cells be an indicator of malignancy?Journal of pathology and translational medicine · 2020
    Article
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Emily PulfordDepartment of Anatomical Pathology, Flinders University of South Australia, Bedford Park, SA 5042, Australia.
Kalyani HuilgolDepartment of Anatomical Pathology, Flinders University of South Australia, Bedford Park, SA 5042, Australia.
David MoffatDepartment of Anatomical Pathology, Flinders University of South Australia, Bedford Park, SA 5042, Australia.
Douglas W HendersonDepartment of Anatomical Pathology, Flinders University of South Australia, Bedford Park, SA 5042, Australia.
Sonja KlebeDepartment of Anatomical Pathology, Flinders University of South Australia, Bedford Park, SA 5042, Australia.ORCID 0000-0002-8976-4714
South Australia Pathology · AUFlinders University · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Malignant mesothelioma (MM) is an aggressive malignancy of the serosal membranes. Early diagnosis and accurate prognostication remain problematic. BAP1 is a tumour suppressor gene commonly mutated in MM. Germline BAP1 mutation has been associated with early onset and less aggressive disease compared with sporadic MM. Sporadic BAP1 mutations are common and are associated with improved survival in MM, contrary to other malignancies. This study investigated the prognostic role of BAP1 in matched cytology and surgical specimens and aimed to investigate the association between BAP1 and the established prognostic marker VEGFA from a cohort of 81 patients. BAP1 mutation was found in 58% of histology and 59% of cytology specimens. Loss of BAP1 expression in both surgical and cytology specimens was significantly associated with poorer survival in a multivariate analysis when controlling for known prognostic indicators. Increased levels of VEGFA in pleural effusions were associated with poor survival. We conclude that the prognostic significance of BAP1 mutations in MM cannot be determined in isolation of other prognostic factors, which may vary between patients. Pathologists should employ caution when commenting on prognostic implications of BAP1 status of MM patients in diagnostic pathology reports, but it may be useful for early diagnosis.

Indexed as

AdultAgedAged, 80 and overBiomarkers, TumorFemaleHumansLung NeoplasmsMaleMesotheliomaMesothelioma, MalignantMiddle AgedMutationPleural Effusion, MalignantTumor Suppressor ProteinsUbiquitin ThiolesteraseVascular Endothelial Growth Factor ABAP1 protein, humanBiomarkers, TumorTumor Suppressor ProteinsUbiquitin ThiolesteraseVascular Endothelial Growth Factor AVEGFA protein, human

Identifiers

PMID29085180
PMCPMC5612603
OpenAlexW2756440722

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.